Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841619 · ClinicalTrials.gov registry record · Early Phase 1
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
A Early Phase 1 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT01841619 is a Early Phase 1 study that has completed, run by University of California, Irvine. The registered enrollment target is 16 participants.
The verdict
NCT01841619, a Early Phase 1 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.
Interventions
- DRUG IVIg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01841619
The ClinicalTrials.gov registry entry for NCT01841619 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IVIg is the first listed.
NCT01841619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01841619 about?
NCT01841619 is a clinical study titled "IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus". The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.
What is the current status of trial NCT01841619?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2013-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01841619?
The interventions under investigation include: IVIg (DRUG).
Who is sponsoring clinical trial NCT01841619?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.